课题基金 / 基金详情

SYNAPTIC LOCALIZATION OF NMDA RECEPTOR PCP MODEL OF SCHIZOPHRENIA

SYNAPTIC LOCALIZATION OF NMDA RECEPTOR PCP MODEL OF SCHIZOPHRENIA
NMDA受体突触定位精神分裂症PCP模型
批准号:
7720351
负责人:
PASQUALE MANZERRA
金额:
$16.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-01 至 2009-05-31

项目摘要

项目成果

PASQUALE MANZERRA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Phencyclidine (PCP) is a non-competitive antagonist of the NMDA glutamate receptor. It produces transient psychosis in normal individuals and exacerbates psychosis in schizophrenics. When administered to rodents, PCP elicits stereotyped behaviors including unrelenting head swaying, digit gnawing and social withdrawal, that are representative of negative signs of schizophrenia in humans. Recent findings have implicated a role for glutamate receptors in schizophrenia. The studies in this project will examine the hypothesis that reduced NMDA receptor function leads to unregulated excitation, disinhibition, and ultimately to neuronal degeneration that contribute to the abnormal cognitive and behavioral manifestations characteristic of schizophrenia. Reduced NMDA receptor function during schizophrenia guides two main hypotheses proposed in this research: (1) that glutamate receptor dysfunction in schizophrenia is dependent on alterations in NMDA receptor subunit composition in the frontal cortex; and (2) that atypical neuroleptics reduce symptoms of schizophrenia through cellular mechanisms that either restore NMDA receptor function or circumvent NMDA dysfunction. Specifically, we will examine whether NR1 subunits of the NMDA receptor are reduced at synaptic sites in frontal cortex of PCP-treated rats compared to control and atypical neuroleptic-treated animals. We will also determine the subunit composition of NMDA receptors at synaptic sites in frontal cortex of PCP-treated rats compared to controls and neuroleptic-treated animals, as well as examine alterations in other proteins within the postsynaptic density (PSD). The primary objective of our research is to contribute to a fundamental understanding of schizophrenia and it?s underlying physiological mechanisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ROLE OF SYNGAP IN REGULATING NMDA RECEPTOR-MEDIATED NEURONAL EXCITOTOXICITY
  • 批准号:
    7959611
  • 项目类别:
  • 资助金额:
    $1.24万
  • 财政年份:
    2009
  • 负责人:
    PASQUALE MANZERRA
  • 依托单位:
SYNAPTIC LOCALIZATION OF NMDA RECEPTOR PCP MODEL OF SCHIZOPHRENIA
  • 批准号:
    7959607
  • 项目类别:
  • 资助金额:
    $9.5万
  • 财政年份:
    2009
  • 负责人:
    PASQUALE MANZERRA
  • 依托单位:
SYNGAP REGULATION OF NMDA RECEPTOR-MEDIATED NEURONAL CELL DEATH
  • 批准号:
    7720359
  • 项目类别:
  • 资助金额:
    $2.06万
  • 财政年份:
    2008
  • 负责人:
    PASQUALE MANZERRA
  • 依托单位:
SYNAPTIC LOCALIZATION OF NMDA RECEPTOR PCP MODEL OF SCHIZOPHRENIA
  • 批准号:
    7627577
  • 项目类别:
  • 资助金额:
    $13.17万
  • 财政年份:
    2007
  • 负责人:
    PASQUALE MANZERRA
  • 依托单位:
海外基金